Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Pancreas Institute, Nanjing Medical University, Nanjing, China.
Front Immunol. 2021 Jun 15;12:673248. doi: 10.3389/fimmu.2021.673248. eCollection 2021.
Hepatocellular carcinoma (HCC) has a high risk of recurrence after surgical resection, particularly among patients with multifocal HCC. Genomic heterogeneity contributes to the early recurrence. Few studies focus on targeted next-generation sequencing (tNGS) to depict mutational footprints of heterogeneous multifocal HCC.
We conducted tNGS with an ultra-deep depth on 31 spatially distinct regions from 11 resected multifocal HCC samples. Matched preoperative peripheral circulating-free DNA (cfDNA) were simultaneously collected. Genomic alterations were identified and compared to depict the heterogeneity of multifocal HCC.
Widespread intertumoral heterogeneity of driver mutations was observed in different subfoci of multifocal HCC. The identified somatic mutations were defined as truncal drivers or branchy drivers according to the phylogenetic reconstruction. and were the most commonly altered truncal drivers in multifocal HCC, while the most frequently mutated branchy driver was . HCC patients with a higher level of intertumoral heterogeneity, defined by the ratio of truncal drivers less than 50%, had a shorter RFS after surgical resection (HR=0.17, p=0.028). Genome profiling of cfDNA could effectively capture tumor-derived driver mutations, suggesting cfDNA was a non-invasive strategy to gain insights of genomic alterations in patients with resected multifocal HCC.
Truncal mutations and the level of genomic heterogeneity could be identified by tNGS panel in patients with resected multifocal HCC. cfDNA could serve as a non-invasive and real-time auxiliary method to decipher the intertumoral heterogeneity and identify oncodrivers of multifocal HCC.
肝细胞癌(HCC)在手术后有很高的复发风险,尤其是在多灶性 HCC 患者中。基因组异质性导致早期复发。很少有研究关注靶向下一代测序(tNGS)来描绘异质性多灶性 HCC 的突变足迹。
我们对 11 例多灶性 HCC 切除标本的 31 个空间上不同的区域进行了 tNGS 超深度测序。同时收集了术前外周游离循环 DNA(cfDNA)的匹配样本。鉴定基因组改变,以描绘多灶性 HCC 的异质性。
在多灶性 HCC 的不同亚灶中观察到广泛的肿瘤间驱动突变异质性。根据系统发育重建,确定了体细胞突变作为主干驱动或分支驱动。和是多灶性 HCC 中最常见的改变主干驱动,而最常突变的分支驱动是。肿瘤间异质性较高的 HCC 患者(定义为主干驱动比例小于 50%),手术后 RFS 较短(HR=0.17,p=0.028)。cfDNA 的基因组分析可以有效地捕获肿瘤衍生的驱动突变,表明 cfDNA 是一种非侵入性策略,可以深入了解多灶性 HCC 患者的基因组改变。
tNGS 面板可在多灶性 HCC 患者中识别主干突变和基因组异质性水平。cfDNA 可作为一种非侵入性和实时辅助方法,用于破译多灶性 HCC 的肿瘤间异质性和鉴定肿瘤驱动基因。